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Abstract
Endothelin-1 (ET-1), a potent vasoconstrictor normally active inmaintaining vascular tone, maymediate significant pathogenic effects,
contributing to several serious diseases when aberrantly expressed or regulated. The present study evaluates the capacity of ET-1 to
affect endothelin-1-associated hypertrophic activity and decreased expression of heme oxygenase-1 by H9c2 rat cardiomyoblasts
in vitro, corresponding to in vivo processes underlying cardiovascular diseases (CVDs). Beta estradiol (β-E) is tested for its capacity
to alter the effects of ET-1. H9c2 cells, cultured 48 h, were stimulated with 100–10,000 nM of ET-1 and evaluated for changes in cell
size, cell viability, and expression of the cytoprotective heat shock protein heme oxygenase-1 (HO-1), with 200 nM ofβ-E included in
selected cultures to evaluate its effect on ET-1-mediated changes. The application of 100 to 10,000 nM of ET-1 resulted in a significant
increase in average cell size and decreases in both cell viability and HO-1 protein content (p< 0.05). Moreover, 200 nM of β-E was
observed to significantly counteract these effects by cardiomyoblasts stimulatedwith 1000 nMof ET-1 (p< 0.05). Sprague-Dawley rats
treated intravenously with 1000 ng/kg of ET-1 demonstrated reduced HO-1 expression in peripheral blood and left ventricular tissue,
which was counteracted by injection of 200 ng/kgβ-E—demonstrating a possible correspondence between in vitro and in vivo effects.
An outcome of particular value for clinical use ofβ-E, in the management of cardiac hypertrophy, is the observed capacity of the drug
to abate ET-1-mediated suppression of HO-1 expression. It has been previously demonstrated that HO-1 inducers exhibit potent
cardioprotective properties, thus offering the promise of combining them with β-E, allowing lower effective dosage of the drug and
concomitantly lower adverse side effects associated with its clinical use. Major findings of this investigation are that pretreatment of
cardiomyoblasts with β-E inhibited their hypertrophic response to ET-1 and counteracts the decrease of cell viability. These effects
were associated with a restoration of HO-1 protein expression in both under in vitro and in vivo conditions.
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Introduction
Cardiopulmonary and cardiovascular diseases (CVDs) lead-
ing to respiratory and heart failure are the major cause of death
and incapacitation in the EU and in many other areas of the
world, particularly in developed nations (Nichols et al. 2013).
These syndromes prominently include abnormal increase in
cardiomyocyte size, with resulting increase in heart size, acute
myocardial infarction (AMI), ischemia-reperfusion (I/R) inju-
ry, and heart function deterioration following AMI (Nichols
et al. 2013). Despite significant advances in early diagnosis,
prevention and therapeutic interventions for these syndromes,
CVD mortality continues to increase worldwide, a phenome-
non that is particularly problematic among aging populations
(Brutsaert 2010). Death rates among persons afflicted with
CVD are very high. More than 50% of heart failure patients
die within 1–4 years of diagnosis, and most afflicted persons
experience significant debilitation during periods of illness
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(Stewart et al. 2001). Currently, CVD imposes an enormously
adverse impact on quality of life, leading to the disruption of
daily management and increasing dependence on caregivers
(Albert et al. 2002). Moreover, despite intensive research ef-
forts, no drugs have yet been developed that definitively pre-
vent or remediate CVD at levels that allow full restoration of
normal life for those afflicted. It is therefore imperative to
develop low-cost preventive and therapeutic countermeasures
for these syndromes, which incorporate both pharmacological
and non-drug interventions.
An essential precondition for identification of novel coun-
termeasures to CVD is development of in vitro cell culture and
animal models of cardiac cellular function that allow rapid
screening of drugs and non-drug inducers of cardioprotective
adaptive responses. The present investigation examines the
effects of endothelin-1 (ET-1), a major physiologic inducer of
hypertrophic changes, on an in vitro model of H9c2 rat
cardiomyoblasts, in experiments that evaluate the capacity of
the drug beta-estradiol (β-E) to attenuate these effects.
Pharmacological strategies for decreasing hypertrophic signal-
ing downstream of ET-1 in cardiomyocytes were suggested by
findings made previously by the authors that antihypertrophic
effects in isolated rat hearts could be achieved by inhibition of
calcineurin activity, with resulting reduction of the nuclear
translocation of NF-AT, a pro-hypertrophic transcription factor
(Haines et al. 2000). These experiments did not include the role
of β-E in signaling; however, it was described in a 2015 report
that a natural compound called tanshinone IIA inhibited estro-
gen receptor-mediated cardiomyocyte hypertrophy through en-
hancement of Akt phosphorylation. This resulted in reduced
expression of calcineurin and subsequent suppression of trans-
location of NF-AT, with consequent inhibition of hypertrophic
signaling (Weng et al. 2015). Interestingly, tanshinone has re-
cently been observed to affect estrogen receptor activity in
ways that alleviates angiotensin II-mediated cardiac hypertro-
phy (Chen et al. 2017). The convergence of this mechanism
with aspects of cardioprotection reported by Haines et al.
(2000) led to speculation that β-E, which is structurally very
similar to tanshinone IIA, also offered potential for affecting
these processes in ways that might ultimately prove valuable in
patient treatment. It was further hypothesized that since
estradiol-mediated cardioprotection through mechanisms that
prominently include induction of heme oxygenase-1 (HO-1)
(Zordoky and El-Kadi 2008), activity of this enzyme would
likely play a role in cellular activities investigated by experi-
ments described in the present report. It is also important to
emphasize that the choice of β-E for this investigation was
based on some intriguing reports, suggesting that it might prove
to be a superior choice for prevention and remediation of
ET-1-mediated disorders. Mounting evidence indicates that
the hormone holds enormous promise in counteracting ET-
1-driven deterioration of both cardiovascular and neurolog-
ical functions in theaftermathofstroke(Stoopetal. 2017).Data
presented in this study reveals notably that administrationof the
hormone following transient middle cerebral artery occlusion
(tMCAO) occurring as a pathological outcome of intracerebral
ET-1 injection resulted in diminished levels of degenerating
neurons and lesser infarct zone magnitude, demonstrating a
clear neuroprotective effect mediated by β-E. These results
may demonstrate the potential for management of cardiac hy-
pertrophy in a model that uses ET-1 treatment to induce the
effects described. The study further suggests that β-E may
prove useful for future clinical management of disorders in
whichET-1 is a contributor to pathogenesis. This drug, a potent
agonist of the nuclear steroid hormone estrogen receptor (ER),
binds to both theα andβ isoforms of this receptor, resulting in
alteration of both gene transcription and protein expression in
cells that express these receptors.Thecompoundmayalsoexert
non-genomic effects through interactionwithmembrane estro-
gen receptors (mERs), such as estradiol-selective G protein-
coupled estrogen receptor (GPER, formerly known as
GPR30) (Prossnitz and Barton 2014).
ET-1 is a 21 amino acid peptide, which is a member of a
family of related proteins expressed ubiquitously by all verte-
brates and utilized primarily for hemodynamic regulation.
Posttranslational regulation of its availability occurs through con-
version of its precursor molecule, called preproendothelin-1
(PPET-1) to the bioactive form, that when expressed by vas-
cular endothelial cells, act as a potent vasoconstrictor
(Agapitov and Haynes 2002). Pathological overproduction
of ET-1 results in excessive pulmonary vascular resistance,
which is a major feature of pulmonary arterial hypertension
(PAH). Blockade of the ET-1 receptor with the sulfonamide
drug bosentan (Tracleer) ameliorates this condition by reduc-
ing pulmonary vascular resistance (Gehin et al. 2016). Cardiac
hypertrophy typically occurs in response to several
stressors—often associated with prior infarction, heart failure,
valvular and ischemic disease, and other conditions. The pri-
mary pathologies may result in effects such as blood volume
or pressure overload and diminished mass of functional con-
tractile tissue (Haines et al. 2000). These features are well-
established characteristics of the hypertrophic heart and have
been known for about half a century at the time of this writing
(Sandler and Dodge 1963; Hood et al. 1968). Hypertrophic
growth may have evolved as an adaptive mechanism allowing
for more efficient utilization of oxygen and reduced wall stress
(Grossman et al. 1975). It has also been reported that both rat
and human hypertrophic right ventricular tissues show upregu-
lation of ET-1 protein levels, which might be a compensation to
preserve contractility (Nagendran et al. 2013). The present in-
vestigation was structured to evaluate a general hypothesis that
the prohypertrophic effects of ET-1 on both cardiomyocytes in
culture and in live animals may be effectively counteracted with
β-E through HO-1-associated mechanisms. One implication of
this study is that use of ET-1 receptor antagonists (ERAs)—
which have regulatory approval for treatment of PAH in several
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countries, might adversely affect right ventricular function
(Nagendran et al. 2013)—hence, studies such as the present
one, which provide improved insight into hypertrophic cellular
processes, will enhance both safety and efficacy of various
therapies for potentially pathological effects of ET-1. β-E is a
potent endocrine modulator which is known to cause adverse
side effects when administered exogenously (Rossouw et al.
2002). Thus, any new clinical protocols to which outcomes
described by the present investigation contribute should take
these properties of the hormones into account as precautions
that caregivers must be aware of.
Most importantly, within the ET-1 dose range tested, this
stimulant significantly increased cell size and decreased both
cell viability and HO-1 protein content and activity after 48 h.
Moreover, as revealed by data shown in this report, β-E at a
dosage of 200 nM significantly counteracted these effects by
cardiomyoblasts and counteracted ET-1-mediated HO-1 sup-
pression. However, it is here acknowledged that effects of ET-
1 andβ-E with biological significance are likely to result from
stimulation outside the dose ranges for both drugs—e.g., after
72 h. Nevertheless, since this investigation was configured as
a preliminary study with the primary purpose of evaluating the
H9c2 rat cardiomyoblast model as an investigative tool, the
dose and time for cell culture treatments appear well-suited for
preliminary demonstration of the cellular response trends of
major interest.
In addition to PAH, inappropriately elevated ET-1 activity is
known to result in awide range of disease conditions, particularly
hypertrophy-associated CVD (Li et al. 2016a). Here, we evaluate
the effect of ET-1 to induce cardiac hypertrophy-associated
phenotypic changes in H9c2 rat cardiomyoblast cells, an
in vitro model with widely accepted reliability in cardiovas-
cular drug discovery (Singh et al. 2015). The outcomes de-
scribed here also include assessment of the capacity of intra-
venously administered ET-1 to affect levels of HO-1 in plasma
and left ventricular heart tissue of Sprague-Dawley rats, an
in vivo model, with acknowledged possible relevance to hu-
man CVD. The experiments described here further assess the
capacity of the anti-inflammatory drug β-E to mitigate the
effect of ET-1, yielding insight as to potential use of β-E in
treatment of diseases in which ET-1 is an etiologic factor. The
experimental design applied to achieve the objectives of the
present study included evaluations of both cellular and sys-
temic effects of ET-1, β-E, and HO-1 in a rat model. These
processes have well-established analogs in humans (Agapitov
and Haynes 2002; Gelfand et al. 1997; Czompa et al. 2014)—
hence, the model used was thus considered appropriate for
providing clinicians and researchers with a paradigm in which
these three agents might contribute to development of future
approaches to management of cardiac hypertrophy.
It is important to emphasize that the present study was not
undertaken with the objective of comprehensively character-
izing the full range of ET-1-induced hypertrophic effects.
Such an investigation would require fairly extensive animal
evaluation of each of the outcome measures shown here,
which would have been beyond the scope of this effort. The
experiments were designed, with a fairly narrow focus, spe-
cifically, to demonstrate the efficacy of a simple, well-
established, and inexpensive in vitro model of cardiac hyper-
trophy as a major investigative tool for more comprehensive
studies—with the corollary benefit for adding insight to ef-
fects of ET-1 and β-E on HO-1 expression, which will have
direct value to both researchers and healthcare providers, who
use activity of this enzyme as a lab biomarker and clinical
correlate of cardiac symptoms.
Materials and methods
Summary of methods: rationale for major features
of experimental design
The present study used H9c2 rat cardiomyoblast cells as an
in vitro model based on their proven capacity to exhibit phys-
iologic responses useful in drug discovery for cardiovascular
medicine (Chen et al. 2013). The useful characteristics of
these cells notably include ET-1-mediated hypertrophic ef-
fects (Li et al. 2016b), cell surface area, and viability (Hua
et al. 2014)—along with outcomes noted by the authors, in
which Western blot analysis was used to determine HO-1
expression by these cells (Csepanyi et al. 2015). Likewise,
Sprague-Dawley rats, the animal model selected for these ex-
periments has a well-established record in cardiovascular re-
search, including investigations conducted by the authors
which also utilize methods described here (Czompa et al.
2014). The animals were anesthetized with ketamine for rea-
sons of compassion and tominimize confounding influence of
stress. One gender (male in this case) was used to avoid po-
tentially confounding influence of sex differences on experi-
mental outcomes. A secondary rationale for selection of male
versus female animals was to be certain that estradiol, a female
sex hormone, exerted effects on male subjects—thus provid-
ing preliminary evidence that the drug holds promise for clin-
ical treatment of ET-1-related pathologies in males—and
probably not limited to female patients.
H9c2 rat cardiomyoblast cell culture
H9c2 rat cardiomyoblast cells (American Type Culture
Collection, Manassas VA, USA) were cultured in Dulbecco’s
modifiedEagle’smedium (DMEM) supplementedwith 10% fetal
bovine serum (FBS) and antibiotics (1% penicillin-streptomycin),
then incubated at 37 °C in the presence of 5% CO2.
Cardiomyoblast cells were plated onto 75-cm2 TPP culture
dishes. Subculturing of cells was conducted serially at approx-
imately 60–70% confluence. The subculturing protocol is
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briefly described as follows: the old medium is first decanted
from the adherent cardiomyoblasts in each plate, then washed
with phosphate-buffered saline (PBS, at pH = 7.4) and incu-
bated in trypsin-EDTA solution for 15 min. Cells were resus-
pended and centrifuged for 6 min at 1100 rpm and at a tem-
perature of 26 °C. After centrifugation, the supernatant was
discarded and the pellets resuspended in fresh FBS mainte-
nance medium. The cells were next cultured on 75-cm2 TPP
plates at a concentration of ~ 100,000 cells/ml.
Induction of hypertrophy in H9c2 cardiomyoblasts
The in vitro hypertrophy induction protocol for the H9c2
cardiomyoblast cell model (Watkins et al. 2010) included treat-
ment with the hypertrophic agonist endothelin-1 (ET-1, E7764,
Sigma, Germany). For these procedures, cardiomyoblasts were
cultured to optimally control the hypertrophic responses of ET-
1. Ethanol (E) served as the solvent in each group.
Cardiomyoblasts were washed, cultured, and treated with
serum-free medium and 1% of antibiotics, in maintenance
DMEM, for the duration of each experiment. Cells were then
incubated for 24 h at 37 °C, and cultured in the presence of 5%
CO2. After 24 h, the cardiomyoblasts were exposed to 100,
1000, and 10,000 nM of ET-1, respectively. Cells were
pretreated with 200 nM of β-E (E2758, Sigma, Schnelldorf,
Germany) for 6 h before exposing to 1000 nM of ET-1.
Cell surface area (cell size)
Morphological studies of H9c2 cardiomyoblasts to evaluate
the magnitude of cell surface area (Pedram et al. 2005) were
accomplished using TPP 24-well plates, in which ~ 8000 cells
per well were cultured on glass coverslips. Cells were treated
as described above, then observed using fluorescence micros-
copy. After 48 h following the hypertrophic challenge, cells
were fixed for 15 min in 4% of formalin, washed three times
and extracted in 0.1% of Triton-X solution for 15 min.
Fluorescein isothiocyanate (FITC)-conjugated phalloidin
was used to visualize cytoskeletal structures and 4′.6-
diamidino-2-fenylindol (DAPI) stain for nuclear elements.
The Zeiss Axio Scope A1 fluorescent microscope was used
with ZEN 2012 software to acquire images and for measure-
ments of cell area in square micrometers (μm2). Microscopy
observations were expressed as the mean of four independent
experiments, using 150 cells in each group.
Cell viability
The viability of H9c2 cardiomyoblast cells was determined fol-
lowing treatmentwith ET-1 andβ-E. Cells were seeded onto TPP
96-wellmicroplates at an average density of ~ 2500 cells perwell.
Cardiomyoblasts were pretreated with β-E, and then cultured for
48 h with the hypertrophic agent ET-1. Next, 20 μl of yellow
MTT (3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium
bromide) was added to cell culture medium at a volume of
5 mg/ml. This compound is reduced to purple formazan in the
mitochondria of living cells, allowing their easy identifica-
tion. Cells were incubated with MTT for 210 min at 37 °C,
followed by removal of this staining medium and resuspen-
sion of purple crystalline marker using isopropyl alcohol.
The cells were next incubated for 30 min in a thermostat
at 37 °C. Absorbance was then measured at wavelengths of
570 and 690 nm, us ing a FLUOSTAR Opt ima
spectrophotometer.
HO-1 protein expression in H9c2 rat cardiomyoblasts
H9c2 rat cardiomyoblasts, approximately 100,000 cells in
each group, were treated with 1000 nM of ET-1, 200 nM of
β-E, and 200 nM of β-E followed by 1000 nM of ET-1,
respectively. Ethanol (E) (0.01%) served as the solvent in
various groups. Following 48 h of culture, HO-1 protein
levels, in drug-free control and each drug-treated group, were
determined. HO-1 proteins were determined at the Food
Analytical Laboratory of University of Debrecen, Hungary,
using the StressXpress™ Human HO-1 ELISA Kit (Enzo
Life Sciences International, Inc., PA, USA). Assays using
the cultured cardiomyocyte model defined by the culture con-
ditions are shown in legend in Fig. 3. Briefly, cells were incu-
bated in 96-well microtiter plate, in each group, coated with an
antihuman HO-1 antibody, followed by treatment with
secondary/detect antibody and related reagents provided with
kits. HO-1 levels were evaluated during the absorbance of the
developed kit reagents at 450 nm in a Biotek ELX 808
Microplate Reader. Results were expressed in nanograms of
HO-1 protein, as median values of each of four ELISA out-
comes (quadruplicates) within the designated interquartile
range for the Enzo kits used to terminate HO-1 assays.
Western blots: in vitro and in vivo
Approximately 100,000 of H9c2 rat cardiomyoblasts (in 1 ml)
were homogenized and lysed in 1 ml isolating buffer contain-
ing 25 mM Tris-HCl, 25 mM NaCl, 1 mM orthovanadate,
10 mM NaF, 10 mM pyrophosphate, 10 mM okadaic acid,
0.5 mM EDTA, 1 mM PMSF, and 1× protease inhibitor cock-
tail. Homogenates were centrifuged at 2000 rpm at 4 °C for
10 min, and the supernatants were transferred to new tubes,
and further centrifuged at 10,000 rpm at 4 °C for 20 min, and
the resultant supernatants were used as cytosolic extract. The
protein concentration was determined by a BCA Protein Assay
Kit (Thermo Scientific, Rockford, IL, USA) using bovine se-
rum albumin (BSA) as the standard. A total of about 100 μg of
protein in each sample were run on 12% acrylamide gels (Bio-
Rad Laboratories, Hercules, CA, USA). Assays for both HO-1
and its reference housekeeping gene (GAPDH) were
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performed on the same blot. The blots were next transferred to
a polyvinylidene difluoride (PVDF) membranes (Bio-Rad
Laboratories, Hercules, CA, USA) for 1 h at 100 V. After
blocking the membranes with 5% of non-fat dry milk in Tris-
buffered saline with 0.1% Tween 20 (TBST), membranes were
incubated overnight with primary antibody solution of HO-1 1/
1000 (Abcam, Cambridge, UK). Antibodies to GAPDH, the
housekeeping gene product used as a referencemarker for assay
of HO-1 protein expression, were obtained from Cell Signaling
Technology, Boston, MA, USA. Subsequent to the above treat-
ment, the membranes were washed with TBST three times and
incubated with the horseradish peroxidase (HRP)-conjugated
secondary antibody solution (1/3000 Cell Signaling
Technology) for 1 h at room temperature. After washing, the
membranes were treated/incubated with Clarity Western ECL
Substrate (Bio-Rad Laboratories, USA) to visualize the bands.
Following the ECL treatment, the membranes were exposed on
X-ray films (Agfa, Mortsel, Belgium). The blots were then
digitalized and analyzed using ImageJ program (Bak et al.
2003; Czompa et al. 2014).
For in vivo studies, following 48 h of treatments with ET-1
(1000 ng/kg), β-E (200 ng/kg), and β-E (200 ng/kg) + ET-1
(1000 ng/kg), respectively, Sprague-Dawley rats (230–290 g)
were anesthetized with ketamine to avoid neuronal and hor-
monal stress as confounding influences in the experiments.
The chest was opened and hearts were excised. Then, blood
was washed out by Krebs-Henseleit buffer via the aorta.
About 10 mg from left ventricular tissue was used, homoge-
nized, and centrifuged for Western blot study. Briefly, myo-
cardial tissue was homogenized and suspended (50 mg/ml) in
sample buffer (10 mMHEPES, pH 7.3, 11.5% sucrose, 1 mM
EDTA, 1 mM EGTA, 1 mM diisopropyl fluorophosphate,
0.7 mg/ml pepstatin A, 10 mg/ml leupeptin, and 2 mg/ml
aprotinin). Proteins were then solubilized with Laemmli solu-
tion [9% SDS (wt/vol), 6% mercaptoethanol (vol/vol), 10%
glycerol (vol/vol), and a trace amount of bromphenol blue dye
in 0.196 M Tris-HCl (pH 6.7)]. Proteins (50 μg protein) were
electrophoresed through 10% SDS-PAGE and transferred to
Immobilon-P membranes (Millipore, Billerica, MA) using a
transfer system (Bio-Rad, Hercules, CA). The blots were
blocked in Tris-buffered saline/Tween-20 with 5% BSA for
1 h and incubated with antibody for recombinant rat HO-1
protein (StressGen Biotechnologies, Victoria, BC, Canada).
Membranes were incubated with anti-goat IgG and were ex-
posed to film (Amersham, UK).
Stimulant effects on HO-1: in vivo studies
Male Sprague-Dawley rats (230–290 g) were purchased from
Charles River Laboratories International, Inc. (Sulzfeld,
Germany). All animals used for experiments in the present
investigation received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No.
85-23, revised 1996) and approved by the local Committee of
the University of Debrecen (UD), Debrecen, Hungary. UD eth-
ical committee approval certificate number: 3/2012/DE MÁB.
Rats were fed with commercial food pellets and water ad
libitum and treated intravenously with 1000 ng/kg of ET-1,
200 ng/kg of β-E, and 200 ng/kg of β-E followed by
1000 ng/kg of ET-1, respectively. Ethanol (E) (0.01%) served
as the solvent in various groups, respectively. After 48 h fol-
lowing the treatment, about 1 ml of venous blood was taken
from untreated and drug-treated rats, centrifuged, and then
plasma HO-1 protein levels were determined using the
StressXpress™Human HO-1 ELISA Kit (Enzo Life Sciences
International, Inc., PA, USA). Plasmawas incubated in 96-well
microtiter plate coatedwith antirat HO-1 antibody, followed by
treatment with secondary/detect antibody and related reagents
provided with kits. Plasma HO-1 levels were evaluated during
the absorbance of the developed kit reagents at 450 nm in a
Biotek ELX 808 Microplate Reader. Results are calculated in
nanograms of HO-1 protein per milliliter of plasma as median
values of each of four ELISA outcomes (quadruplicates, n = 8
measurements) within the designated interquartile range for the
Enzo kits used to accomplish these HO-1 assays.
Statistical analyses
Results of cell surface area (cell size), cell viability, and HO-1
protein expression were compared between groups by using
analysis of variance (ANOVA) followed by Dunnetts’s test
(Wallenstein et al. 1980). The results obtained in each drug-
treated group were compared to the values obtained in the
drug-free control (C) or the 1000 nM of ET-1-treated group,
respectively. The values obtained were expressed as the means
± standard error of the means (SEM) and were considered
significantly different at p < 0.05.
Results
Cell surface area changes in response to hypertrophic
stimulus
The histogram in the upper panel of Fig. 1 demonstrates that
H9c2 cells treated with 100, 1000, and 10,000 nM of ET-1
exhibited significant increases in the average cell surface areas
(representing cell size), in the presence or absence of ethanol
(E) in comparison with the drug-free control value (C)
(p < 0.05). Ethanol (E) concentration was constant in each of
the experimental conditions described. It was further noted
that treatment with ethanol or β-E did not cause significant
changes in cell size and other outcomes measured when re-
sults were comparedwith data obtained from drug-free control
group (C). Continuation of these studies, in which cells were
Naunyn-Schmiedeberg's Arch Pharmacol
treated with 200 nM of β-E, followed by stimulation with
1000 nM of ET-1, revealed that β-E-mediated significant sup-
pression of cell surface area increase—induced by 1000 nM
ET-1. The lower panel of Fig. 1 shows representative size
comparisons of cells in the drug-free control (C) and β-E-
and ET-1-treated groups. These photographs demonstrate that
cells treated with 100, 1000, and 10,000 nM of ET-1, respec-
tively, resulted in cell volume increases, with β-E-mediated
suppression of this hypertrophy-associated effect. These re-
sults demonstrate that coadministration of 1000 nM of ET-1
and 200 nM of β-E resulted in a reduction in cell size in
comparison to cells cultured with 1000 nM of ET-1.
Stimulant effects on cell viability
As shown in Fig. 2, relative to viability of cells cultured in
unsupplemented medium, cardiomyocytes grown in 0.01% of
ethanol and 200 nM of β-E, were not significantly affected.
Conversely, it was observed that treatment with ET-1 signifi-
cantly reduced viability of cells administered 100–10,000 nM
of this stimulant. It was further noted that pretreatment of cells
with 200 nM of β-E significantly protected against ET-1-
mediated cell death in comparison with the entire dose range
evaluated.
Stimulant effects on expression of HO-1: in vitro
studies
Expression of HO-1 protein by H9c2 rat cardiomyoblasts in
response to indicated stimulation conditions for 48 h is shown
in Fig. 3. The histogram in the upper part of the Fig. 3 demon-
strates that cells cultured with 1000 nM of ET-1 in medium
containing 0.01% of ethanol (ET-1 + E, 1000 nM), produced
significantly less HO-1 than those incubated in unsupplemented
Fig. 1 Cell surface area magnitude changes in response to hypertrophic
challenge. The surface area of H9c2 rat cardiomyoblasts was measured in
cells cultured under the following conditions: unsupplemented cell
culture medium (control, C), cell culture medium containing 0.01% of
ethanol (E), 200 nM of β-estradiol (β-E) in medium containing 0.01% of
ethanol (200 nM β-E + E), 100 nM of endothelin-1 (100 nM ET-1) in
medium containing 0.01% of ethanol (100 nM ET-1 + E), 1000 nM of
ET-1 in unsupplemented cell culture medium (1000 nM ET-1), 1000 nM
of ET-1 in medium containing 0.01% of ethanol (1000 nM ET-1 + E),
10,000 nM of ET-1 in medium containing 0.01% ethanol (10,000 nMET-
1 + E), and 200 nM of β-E and 1000 nM of ET-1 in medium containing
0.01% of ethanol (200 nM β-E + 1000 nM ET-1 + E). Outcomes are
expressed in square micrometers of cell surface area (μm2) ± SEM. n =
200 cells in each group. *p < 0.05 with respect to comparisons made to
the drug-free control culture (C) value, and +p < 0.05 compared to the
average percent cell viability evaluated in the 1000 nM of ET-1 + E group
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drug-free medium (C) (P < 0.05). The effect of β-E on cardio-
myocyte expression of the enzyme, assessed by treatment with
200 nM of β-E with 0.01% of ethanol included as a solvent for
the drug (β-E of 200 nM+E), revealed no significant alteration
by these stimulation conditions relative to cells grown in
unsupplemented control (C) medium. β-E at a dosage of
200 nM was observed to result in significantly restored HO-1
expression by cardiomyoblasts treated with 1000 nM of ET-1
(β-E of 200 nM+ET-1 of 1000 nM+E) relative to cells cul-
tured with 1000 nM of ET-1 without β-E (ET-1 of 1000 nm +
E) (P < 0.05). Results of Western blot analysis shown in the
lower frame of Fig. 3 revealed bands corresponding to HO-1
(MW= 32 kDa) and GAPDH (MW=37 kDa), detection anti-
bodies for which were obtained from Cell Signaling
Technology (Boston,MA, USA). Subjective visual comparison
of relative band intensity for HO-1 protein parallels outcome
shown in Fig. 3, demonstrating three major results: first, that
ET-1 treatment of cardiomyoblasts suppresses HO-1 protein
levels and expression; secondly, that β-E alone has no signifi-
cant effect on production of the enzyme; and thirdly, that β-E is
capable of restoring a significant fraction of HO-1 expression
by cells, in which it is suppressed by ET-1 (1000 nM) treatment.
Stimulant effects on HO-1: in vivo studies
Plasma HO-1 protein levels in peripheral plasma collected
48 h following intravenous treatment of rats with endothelin-
1 and β-E are shown in the upper panel of Fig. 4. Data
shown by histogram displays in the upper panel of the
Fig. 4 demonstrate that relative to serum of untreated animals,
plasma from rats treated with 1000 ng/kg of ET-1 contained
significantly lower amounts of HO-1 protein (P < 0.05).
Whereas plasma HO-1 levels in animals coadministered
1000 ng/kg of ET-1 with 200 ng/kg of β-E, exhibited HO-1
content with no statistically significant difference from levels
of the enzyme in untreated control (C) rats. Outcomes of the
evaluation of β-E effect on plasma HO-1 levels also shown in
the upper panel of Fig. 4 reveal that animals receiving 200 ng/
kg of this drug exhibit HO-1 content of plasma not significant-
ly different from plasma of rats receiving 1000 ng/kg of ET-1
and 200 ng/kg β-E, or untreated control animals. Results of
representative Western blots conducted on myocardial tissue
collected 48 h following ET-1 and β-E administration are
shown in the middle panel of Fig. 4. These results show bands
corresponding to HO-1 (MW= 32 kDa) and GAPDH (MW=
37 kDa) in the lower panel of Fig. 4. Visual comparison of
relative band intensity for HO-1 protein parallels outcomes of
assays for HO-1 shown in the upper panel of the Fig. 4.
Specifically, data in Fig. 4 demonstrates that intravenous ET-
1 treatment reduces HO-1 expression in both plasma andmyo-
cardial tissue. Results shown in Fig. 4 also demonstrate thatβ-
E alone has no significant effect on HO-1 expression in plas-
ma or myocardial tissue. Results shown in the middle panel of
Fig. 4 represent outcomes of an experiment which was con-
ducted to generate a representative qualitative picture of
response of the model to stimulation—without statistical
workup (i.e., non-quantitative study). These in vivo outcomes
were intended to provide a rough single visual indicator of
Fig. 2 Effect of hypertrophic challenge on cell viability in cell cultures.
H9c2 cardiomyoblast viability was assessed using the MTT assay in the
following groups: unsupplemented cell culture medium (control, C), cell
culture medium containing 0.01% of ethanol (E), 200 nM of ß-estradiol
(β-E) inmedium containing 0.01% of ethanol (200 nMβ-E + E), 100 nM
of endothelin-1 (ET-1) in medium containing 0.01% ethanol (100 nMET-
1 + E), 1000 nM of ET-1 in unsupplemented cell culture medium
(1000 nM ET-1), 1000 nM of ET-1 in medium containing 0.01% of
ethanol (1000 nM ET-1 + E), 10,000 nM of ET-1 in medium containing
0.01% ethanol (10,000 ET-1 + E), and 200 nM of β-E and 1000 nM of
ET-1 in medium containing 0.01% of ethanol (200 nM β-E + 1000 nM
ET-1 + E). n = 150 in each group. *p < 0.05, comparisons were made to
the drug-free control (C) value; +p < 0.05, comparisons were made to the
ET-1 (1000 nM ET-1) and all ET-1 + E-treated groups
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HO-1 expression response for the purpose of extending this
and future study design in ways that will allow improved use
of the animal model in HO-1 expression investigations. It is
important to note that the effect of ET-1 or its release by tissue
is very different in cell models, isolated organ models, or
intact animals (Szolcsanyi et al. 2001; Lekli et al. 2008).
Finally, these outcomes reveal that β-E is capable of preserv-
ing production of the enzyme systemically and by heart tissue.
Discussion
Emerging trends in investigation of the biological properties
of ET-1 and relevance of this vasoactive protein to cardiopul-
monary disorders are driven substantially by recognition that
Fig. 3 ELISA analysis of heme oxygenase-1 (HO-1) protein levels and
Western blots in in vitro cell culture. H9c2 rat cardiomyoblast expression
of HO-1 protein was assessed in cells cultured under the following con-
ditions: unsupplemented cell culture medium (control, C), 1000 nM ET-1
in medium containing 0.01% of ethanol (1000 nM ET-1 + E), 200 nM β-
estradiol in medium containing 0.01% of ethanol (200 nM β-E + E), and
200 nM of β-E and 1000 nM of ET-1 in medium containing 0.01%
ethanol (200 nM β-E + 1000 nM ET-1 + E). ELISA analysis results
shown in the upper panel for HO-1 protein levels. Results are shown as
average HO-1 levels. n = 8 in each group. Western blot representative
bands corresponding with the bars (figure upper part), shown in the mid-
dle panel, was obtained from cytosolic extracts of cardiomyoblast lysates.
The expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was measured as a reference housekeeping protein (lower panel).
*p < 0.05, comparisons were made to the drug-free control (C) value;
+p < 0.05, comparisons were made to the ET-1 + E (1,000 nM)-treated
group
Fig. 4 ELISA analysis of heme oxygenase-1 (HO-1) protein levels in
plasma and Western blots in myocardial tissue. HO-1 levels in plasma
protein (upper panel) and expression of HO-1 protein (middle panel) in
left ventricular tissue assessed under the following conditions: rats were
treated with (i) 1000 ng/kg of endothelin-1 (1000 ng/kg ET-1 + E), (ii)
200 ng/kg of β-estradiol (200 ng/kg β-E + E), and (iii) 200 ng/kg of β-E
and 1000 ng/kg of ET-1 (200 ng/kg β-E + 1000 ng/kg ET-1 + E), respec-
tively. Ethanol (E) was the solvent at a final concentration of 0.01% in
each sample. Results are shown as average of HO-1 plasma protein levels
(upper panel). n = 8 (quadreduplicated) in each group. Western blot rep-
resentative bands corresponding with the bars (upper part), shown in the
middle panel, was obtained from lysates of left ventricular tissue. The
expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
shown as a reference housekeeping protein (lower panel). *p < 0.05, com-
parisons were made to the drug-free control (C) value; +p < 0.05, com-
parisons were made to the ET-1 (1000 ng/kg)-treated group
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this molecule is a critical factor in pathogenesis of diseases
such as pulmonary arterial hypertension (PAH) (Kylhammar
and Radegran 2016). Etiologic contributors to these diseases
prominently include chronic exposure to aerial pollutants, in
particular oxides of nitrogen and sulfur and partly combusted
fuels (Cheng et al. 2015; Velicka et al. 2015; Ghanbari
Ghozikali et al. 2016). Public health policies in nations with
severe air pollution problems, particularly the People’s
Republic Of China, have responded to the burden placed on
their medical care facilities by prioritizing support for research
into ET-1 and other biomolecules that affect respiratory and
cardiovascular function (Pan et al. 2010; Luo et al. 2012). The
present study evaluates strategies for affecting disease-
associated ET-1 effects using the H9c2 rat cardiomyoblast
model, which is widely used for investigation of cellular as-
pects of cardiovascular pathologies. This in vitro system is
here utilized for evaluation of the ability of β-E to counteract
effects of ET-1, which are features of ET-1-mediated diseases,
including cardiac hypertrophy and pulmonary arterial hyper-
tension. The results demonstrate that ET-1 stimulates changes
in H9c2 cardiomyoblast cells that are also observed in cardiac
hypertrophy, including increases in cell size (Porchia et al.
2008) and decreased viability (Xu et al. 2010) and reduced
expression of HO-1 protein (Liou et al. 2015). The outcome of
studies conducted to demonstrate ET-1-mediated changes in
cell size, shown in Fig. 1, clearly indicates that major effects of
this stimulation is observed in a dose range from 0 to
10,000 nM of ET-1. Outcomes in this interval represent a
plateau value for cell size increase in this model. The absence
of significant cell size increase in response to presence of
0.01% ethanol in culture media indicates its value for use as
a solvent for β-E. Moreover, since 200 nM of β-E did not
independently induce significant H9c2 cell size increase, this
drug was considered appropriate for evaluation of ET-1 effects.
The capacity of 200 nM of β-E to significantly attenuate
1000 nM of ET-1-mediated cell size increase demonstrates
the utility of this drug in counteracting this feature of patho-
logical processes in which ET-1 is a key factor.
The results of representative H9c2 cardiomyoblast cell fluo-
rescentmicroscope images revealed increases of cell sizes under
each ET-1 stimulation condition, occurring in parallel to
ET-1-mediatedinductionofcell size increases.Althoughmech-
anistic studies were not conducted to determine molecular
mechanisms of ET-1-induced increased cardiomyocyte size,
previous work by other investigators demonstrated that the pro-
tein simulates high levels of activity by mammalian target of
rapamycin (mTOR), a serine/threonine protein kinase which is
a central regulator of cellular metabolism, growth, and survival
in response to stressors, nutrients, growth factors, and hor-
mones—moreover, ET-1-induced increases in mTOR activity,
acts on a feline model of adult cardiac muscle cells to stimulate
phosphorylation signalingwhich contributes to hypertrophic ef-
fects (Moschellaetal.2007).Thiseffect isprobablyanelementof
mTOR-dependentprocessespromotingsize increasesof thekind
observed in H9c2 cells described in the present study.
Interestingly, similar mTOR-dependent mechanisms contribute
togeroconversionofhumancells topro-inflammatory senescent
forms—an underlying feature of physical deterioration occur-
ring as a main aspect of the aging process (Haines et al. 2013;
Leontieva et al. 2015). Overactivity of this enzyme often arrests
celldivisionbutallowsaccumulationofproteinprecursors tocell
structural elements, resulting in increasedcell sizeanddisruption
of normal physiologic functions, along with high expression of
inflammatory mediators, which in turn cause dysregulation of
tissue homeostasis—and a wide range of pathological effects
(Haines et al. 2013; Leontieva et al. 2015).
The effects of ET-1 challenge on H9c2 viability were
assessed using the colorimetric MTT assay as described.
Outcomes of these experiments are shown in Fig. 2. Relative
to viability of cells grown in unsupplemented control media,
the significant decrease in H9c2 viability observed in cells
treated with 100–10,000 nM of ET-1 was expected based on
previous studies (Funayama et al. 2013). The mechanism by
which ET-1 decreases viability of cardiomyocytes also ap-
pears to involve disruption of normal protein metabolism
(Funayama et al. 2013). Dose-response evaluations were con-
ducted for the effect of ET-1 on cells at 0, 100, 1000, and
10,000 nM (Figs. 1 and 2). Based on the outcomes of ET-1
alone, the experiments were designed to evaluate the effect of
β-E at the stimulation levels shown by ET-1, on the assump-
tion that below the dose of 100 nm of ET-1, β-E effects would
not have produced significant changes in comparison with the
drug-free control (C) value in our in vitro model system.
Western blot data outcomes shown in Figs. 3 and 4 are most
clearly interpreted in the context of results shown in the pre-
vious figures. Here again, it is important to note that ethanol at
the concentration used failed to significantly influence any of
the outcome variables measured; moreover, β-E alone like-
wise did not cause significant alterations in any of the effects
measured. It is nevertheless important to note that 200 nM of
β-E interacted with cultured cells subjected to 1000 nMof ET-
1 to counteract hypertrophic effects of the molecule as
shown in Figs. 1, 2, and 3. As part of the experimental design,
the authors utilized these outcomes as a rough guide to estab-
lish the in vivo experiments in HO-1 protein expression by
live rats treated with ET-1 (Fig. 4). This experimental strategy
is nevertheless subject to an important caveat: specifically, the
Western blot assays both for cultured cells (Fig. 3) and for live
animals were configured as qualitative evaluations of
ET-1-mediated induction of HO-1. Here, the authors acknowl-
edge that the data shown in Figs. 3 and 4 absolutely do not
demonstrate definitive and precisely reproducible correlations
between ET-1 stimulation and hypertrophic effects. Instead,
the outcomes provide readers who may consider using this
study as a starting point for more comprehensive analysis of
approaches to counteracting pathologies, in which ET-1 plays
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a role, particularly in development of safety and efficacy stud-
ies described in the introductory section of the present paper.
The results of the present study provide improved insight
into specific effect of ET-1 on cells of the heart and the ability
of β-E to remediate them. The findings described here will
allow improved focus of experimental design for ongoing basic
scientific investigations and human clinical evaluations of β-E
therapy of disorders, in which ET-1 is a key contributor. The
effects of ET-1 on HO-1 production or expression are particu-
larly intriguing in the context of β-E use in patient care. β-E is
an estrogen sex hormone, important in the regulation of the
estrous and female menstrual cycles. It thus has significant ad-
verse effects, including increased triglycerides, which exacer-
bates cardiovascular disorders (Gelfand et al. 1997). For this
reason, naturally occurring, generally regarded as safe (GRAS)
formulations which interact additively or synergistically with
β-E to decrease its effective dosage, are of potentially enor-
mous clinical value. Recently, HO-1 inducers have been recog-
nized as being valuable for treatment of cardiovascular, lung,
neurological, and kidney disorders (Haines et al. 2012), along
with osteoarthritis as described above (Mahmoud et al. 2015).
Results of in vitro studies described above were paralleled
by outcomes of experiments using a Sprague-Dawley in vivo
rat model, in which peripheral blood plasma and left ventricular
heart tissue animals treated intravenously with ET-1 and β-E,
were assessed for expression of HO-1 protein. These data,
shown in Fig. 4, reveal that relative to drug free animals periph-
eral plasma and cardiac muscle HO-1 content of ET-1-treated
rats is significantly reduced. This result is consistent with find-
ings made by similar analyses of cultured cardiomyocyte re-
sponse to ET-1 stimulation, an indicator of correlation, expected
between potentially pathological increases in ET-1 and dimin-
ished protective capacity of HO-1. Specifically, these outcomes
provide additional evidence that capacity of the enzyme to
counteract deleterious effects of aberrantly increased ET-1
levels in cardiovascular syndromes is impaired by influences
that promote high ET-1 expression, systemically and in heart
muscle tissue (Bak et al. 2003; Czompa et al. 2014). The find-
ings are also significant for potential use of β-E as a primary
therapeutic for disorders involving elevated ET-1 expression.
Here, the investigators demonstrate that rats treated indepen-
dently with the drug did not significantly affect HO-1 expres-
sion in blood or heart tissue in any adverse ways and restored
HO-1 production to into the range of that measured in untreated
control animals when given to ET-1-treated rats.
Although not specifically studied in the present investiga-
tion, it is of interest to note the findings of Csonka et al.
(1999), Szabo et al. (2004), Bak et al. (2006). In their studies,
authors of the abovementioned publications demonstrated a
close correlation between hypertrophy-associated cellular ef-
fects and HO-1 expression and/or enzyme activities by vari-
ous interventions under in vitro and ex vivo conditions in
various tissues.
The results shown here demonstrate that ET-1 suppresses
expression of HO-1 in H9c2 cardiomyoblast cells, thereby
diminishing the cardioprotective effect of this enzyme. This
result is consistent with previous studies by authors of the
present report, revealing that phytochemical HO-1 inducers,
typically with low or negligible occurrence of adverse side
effects, are potently cardioprotective (Juhasz et al. 2013;
Czompa et al. 2014; Csiki et al. 2015). These outcomes also
demonstrate that HO-1 inducers offer corollary application for
prevention and treatment of other severe chronic diseases,
including eye disease (Szabo et al. 2004; Varga et al. 2013),
type 2 diabetes (Mahmoud et al. 2013), rheumatoid arthritis
(Mahmoud et al. 2014), and osteoarthritis (Mahmoud et al.
2015). These experiments did not include β-E commonalities
in signaling affected by this compound as described in a 2015
report, and it was presented that a natural compound called
tanshinone IIA inhibited estrogen receptor-mediated cardio-
myocyte hypertrophy through enhancement of Akt phosphor-
ylation, resulting in reduced expression of calcineurin and
subsequent suppression of translocation of NF-AT, with con-
sequent inhibition of hypertrophic signaling (Weng et al.
2015). Interestingly, tanshinone has recently been observed
to affect estrogen receptor activity in ways that alleviates an-
giotensin II-mediated cardiac hypertrophy (Chen et al. 2017).
The convergence of this mechanism with aspects of
cardioprotection reported by Haines et al. (2000) led to spec-
ulation that β-E, which is structurally very similar to
tanshinone IIA, also offered potential for affecting these pro-
cesses in ways that might ultimately prove valuable in patient
treatment.
Conclusions
Two major findings emerging from analysis of data produced
by the present study are (i) that ET-1 exerts prohypertrophic
effects in the rat heart and reduces the expression of the
cardioprotective enzyme HO-1, and (ii) that β-E attenuates
these ET-1 effects. These effects have been demonstrated both
in vitro and qualitatively in an in vivo model. The results of
the present study thus open a line of drug discovery, in which
the benefit of β-E may be greatly augmented by coadminis-
tration of phytochemical HO-1 inducers. The precise mecha-
nism by which β-E achieves this protective effect via the
stimulation of HO-1 remains to be resolved. Finally, results
of the present investigation may underscore the value of ther-
apeutic inducers of HO-1 in both prevention and treatment of
a wide range of serious chronic disease. Particularly exciting
is a recent demonstration that Bnon-drug^ methods for ampli-
fication of this enzyme may be used to precisely target root
pathomechanisms of chronic inflammatory disease, with dra-
matic improvement of prognoses of human patients (Haines
et al. 2012).
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